European Study Provides New Insight into Public Interest in Medicines Research
(14 April 2015) - Researchers at The University of Manchester and Central Manchester University Hospitals NHS Foundation Trust (CMFT) have published data for the first time about public knowledge of and interest in the process of medicines
Medicines R&D describes the entire process of bringing a new medicine to patients – from laboratory studies to clinical studies, then regulatory approval and further evaluation during clinical use.
The data, which is segmented by type of medicines R&D (e.g. safety, clinical trials, patients’ roles), demographics, country, and level of previous experience in the
By providing an extensive insight into people’s knowledge and interests, the researchers hope the data will help drive public involvement in medicines R&D, which is the main objective of the
Dr. Lode Dewulf, Chief Patient Affairs Officer at UCB, partner in the project, commented, “We need better studies to answer more relevant questions more efficiently and faster. Collaboration between study sponsors and (future and experienced) study participants is needed for this. But we often lack the required understanding to have such collaboration for all studies. Thus, this survey and its findings greatly contribute to the understanding we need.”
A key finding of the
“We are all potential patents,” said Kathy Oliver, Co-Chair of
The study which surveyed almost 7000 people across Europe is part of the European Patients’ Academy on
Suzanne Parsons, Health Researcher at The University of Manchester and Central Manchester University Hospitals NHS Foundation Trust and lead researcher for the study, explained: “The survey reveals that over 75 per cent of respondents had no or less than good knowledge about medicines
“The data generated through our study will be a powerful tool for the
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025